Advanced therapies program · Operating model
Bringing End-to-End Visibility to a No-Fail Advanced Therapies Supply Chain
I took on an advanced therapies initiative built around a question that was hard to ignore: If a $12 pizza can be tracked end to end, from order placed to dough made, oven, quality check, driver assigned, en route, and delivered, why couldn't a $500,000 life-saving therapy be tracked with the same clarity?
That contrast exposed a real operational failure in a setting where the stakes were incomparably higher.
Children waiting for cell therapy were depending on a treatment manufactured from their own cells and moving through an extremely time-sensitive supply chain of manufacturing, logistics, and clinical coordination. In some cases, the therapy had a very limited viability window. A breakdown in handoff, timing, temperature control, environmental monitoring, or chain of custody and identity could put the treatment itself at risk. Families were left waiting for a life-saving therapy with little real visibility into where it was, whether it was safe, and when it would arrive.
A major professional services firm had secured millions in funding to prototype a patient tracking platform for this category. The vision was clear: create visibility across the full journey from patient onboarding, sample collection through manufacturing, transport, and infusion readiness. The team was in place. The investment was approved. But no one had yet been able to thread the system together into something workable.
The Challenge
This was not a single-system integration problem. It was a high-risk coordination problem across a fragmented ecosystem.
Critical data lived in different places and belonged to different stakeholders. Manufacturing teams worked through lab and production systems. Logistics providers managed location, custody, and cold-chain conditions across separate platforms, often with competing commercial interests. Hospitals had their own intake systems, privacy requirements, and clinical workflows. Care teams needed timing and readiness information. Regulators expected traceability and auditability at every handoff.
Every piece mattered. Every stakeholder had part of the picture. No one could see the whole picture clearly enough to make it useful for the people who needed it most.
The technical challenge was substantial, but the real difficulty was orchestration. The platform had to bring together hundreds of data points across manufacturing status, chain of custody, environmental conditions, transport milestones, intake confirmation, and treatment readiness. It had to do that in a way that was HIPAA-compliant, operationally workable, and capable of standing up to regulatory scrutiny on every data point and every handoff.
And there was no true analogue to borrow from. This was not conventional pharma distribution. It was not parcel tracking. It was not organ transport. The patient was also the source of the raw material, and the therapy had to make its way back to that same patient under exacting conditions, within a chain where failure could mean there was no second chance.
What I Did
I reframed the problem in a way that made it actionable.
Instead of approaching it as a conventional IT integration exercise, I pushed the team to think in terms of end-to-end visibility. If a pizza could be tracked through every meaningful status change, then a life-saving therapy could too. That became a practical way to cut through complexity and focus the work on what actually mattered: who needed to know what, when, and in what form.
From there, I mapped the core processes and identified the information needs of each stakeholder group.
Manufacturing teams needed production status, cell viability, and quality checkpoints. Logistics providers needed pickup confirmation, location, environmental monitoring, and custody tracking. Hospitals needed arrival timing, intake verification, and coordination signals tied to infusion readiness. Clinicians needed visibility into timing and patient preparation windows.
Parents needed something different. They did not need technical overload, but they also should not have been left with questions. My view was simple: do not overwhelm families in crisis with operational detail, but do not hide behind abstraction either. I helped shape simple, honest status updates that surfaced the information that care teams actually needed: is the therapy coming, when will it arrive, and is it safe?
That clarity became the breakthrough. Once the data relationships were made visible in a coherent model, senior stakeholders could finally see how the ecosystem could work as a connected system rather than a set of disconnected functions.
I then helped align the stakeholder groups around an executable path forward. That meant working through lab teams whose systems were not designed for external interoperability, navigating logistics providers operating on different platforms with competitive boundaries, addressing hospital workflow and privacy concerns through HIPAA-compliant design, and ensuring the resulting audit trail could satisfy regulatory expectations at every critical stage.
From that foundation, I led a lean product effort that built template applications for different stakeholder groups, a foundational data exchange layer, and direct integrations with source systems. The goal was not just technical connectivity. It was operational trust: creating a model that multiple manufacturers, providers, and hospital sites could actually use.
The Result
I helped turn a fragmented, no-playbook therapy supply chain into a working visibility model for one of the most demanding environments in healthcare.
The result was a validated platform approach that improved operational visibility for clinicians, gave care teams greater transparency during a critical time, and created a practical framework for tracking high-value, time-sensitive therapies across manufacturing and delivery.
Across related engagements, the work went on to support programs spanning multiple manufacturers and hundreds of hospital sites, serving thousands of patients who all needed the same thing: visibility and certainty that their life-saving therapy would arrive on time and be viable.
Beyond the immediate operational impact, the broader platform investment became a major strategic asset. The program ultimately contributed to the creation of a high-value enterprise asset later valued at approximately $500 million. More importantly, it helped establish an operating model for a category that had no established blueprint; bringing structure, visibility, and confidence to a bi-directional supply chain where the consequences of uncertainty were measured in patient outcomes.